Pharma IP Rights In China: Avoiding The Antitrust Pitfalls

Law360, New York (April 29, 2013, 12:41 PM EDT) -- Antitrust authorities globally are grappling with competition claims in the pharmaceutical sector. Recognizing that inventive pharmaceutical companies are entitled to protect their valuable intellectual property rights, antitrust authorities or courts will consider intervention to protect competition or even assess the value of the IPR.

The attitude of China to the protection of IPR has been put in the spotlight recently by the release by the State Administration of Industry and Commerce (SAIC) of the fifth draft of Guidelines on Enforcement of Anti-Monopoly Law in the Area...
To view the full article, register now.